Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of tetrahydrocannabidivarin in preparation of medicine for treating pulmonary arterial hypertension and medicine composition containing tetrahydrocannabidivarin

A technology of tetrahydrocannabinol and pulmonary arterial hypertension is applied in reducing the medicinal side effects caused by bosentan, and the application field of medicine can solve problems such as functional differences.

Active Publication Date: 2021-03-30
YUNNAN HEMPMON PHARMA CO LTD
View PDF9 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

It can be seen that although they are all cannabinoids, due to the difference in structure, the functions of each substance in cannabinoids are significantly different.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of tetrahydrocannabidivarin in preparation of medicine for treating pulmonary arterial hypertension and medicine composition containing tetrahydrocannabidivarin
  • Application of tetrahydrocannabidivarin in preparation of medicine for treating pulmonary arterial hypertension and medicine composition containing tetrahydrocannabidivarin
  • Application of tetrahydrocannabidivarin in preparation of medicine for treating pulmonary arterial hypertension and medicine composition containing tetrahydrocannabidivarin

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0045] Experiment 1: THCV can effectively inhibit pulmonary hypertension caused by hypoxia

[0046] 1. Grouping of experimental animals

[0047] 4-6 weeks old, healthy and lively, with shiny coat color, weighing (25.15±2.15) g, C57BL / 6 (Experimental Animal Center of Military Science and Medical College, SPF grade). Divided into seven groups:

[0048] Group 1 (normoxia wild type, as a control group): under normoxic conditions, 10 female mice and 10 male mice;

[0049] Group 2 (anoxic wild type, as a control group): under hypoxic conditions, 10 female mice and 10 male mice;

[0050] Group 3 (hypoxic bosentan, as a control group): intragastric administration under hypoxic conditions, 10 female mice and 10 male mice at 100 mg / kg;

[0051] Group 4 (hypoxic prostaglandin, as a control group): gavage treatment under hypoxic conditions, 10 female mice and 10 male mice at 40 μg / kg;

[0052] Group 5 (4mg / kg THCV, hypoxia experimental group): intragastric administration under hypoxic...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a novel application of tetrahydrocannabidivarin (THCV). The application comprises preparation of a medicine for treating pulmonary arterial hypertension, and application to combined use with bosentan for reducing the side effect of bosentan in treating pulmonary arterial hypertension. The invention also provides a pharmaceutical composition for treating pulmonary arterial hypertension. The pharmaceutical composition comprises tetrahydrocannabidivarin and a medicinal carrier suitable for treating pulmonary arterial hypertension. The invention also provides a pharmaceutical composition for treating pulmonary arterial hypertension in combination with bosentan, wherein the pharmaceutical composition comprises tetrahydrocannabidivarin, bosentan and a medicinal carrier suitable for treating pulmonary arterial hypertension, and is used for treating pulmonary arterial hypertension and reducing liver toxicity caused by the use of bosentan.

Description

technical field [0001] The invention relates to the application of tetrahydrocannabidivarin (THCV) in the preparation of medicaments, especially the application in the preparation of medicaments for treating pulmonary hypertension. The present invention also includes the use of tetrahydrocannabinol for reducing medicinal side effects caused by bosentan. The invention provides a pharmaceutical composition containing tetrahydrocannabinol, which can be used to treat pulmonary hypertension, and can also be used in combination with bosentan to reduce the side effect of bosentan. Background technique [0002] Pulmonary arterial hypertension (PAH) has complex etiology and is caused by a variety of heart, lung or pulmonary vascular diseases. Pulmonary hypertension is currently an incurable disease with a high mortality rate. [0003] Pulmonary arterial hypertension is characterized by pathological features of pulmonary arteriolar vascular remodeling and pulmonary artery vascular s...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/352A61K31/506A61P9/12A61P11/00
CPCA61K31/352A61K31/506A61P9/12A61P11/00A61K2300/00
Inventor 郭仰东于朝晖郭佩兰连萌赵丽梅常坦然
Owner YUNNAN HEMPMON PHARMA CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com